Lentiviral vectors plko 1

Manufactured by Merck Group

Lentiviral vectors (pLKO.1) are a type of genetic delivery system used for the stable transduction of target cells. These vectors are derived from the human immunodeficiency virus (HIV) and are designed to efficiently deliver genetic material into a wide range of cell types, including dividing and non-dividing cells. The pLKO.1 vector backbone contains the necessary elements for viral packaging, reverse transcription, and integration into the host cell genome.

Automatically generated - may contain errors

Lab products found in correlation

Puromycin, by Takara Bio (2 mentions) X tremegene, by Roche (1 mentions)

Close spelling variants of this product

PLKO.1 lentiviral vectors for shRNAs (2 citations) Lentiviral pLKO.1-puro vectors (4 citations) Puromycin-resistant lentiviral vectors (pLKO.1-puro) (2 citations) PLKO.1 lentiviral vector (28 citations) PLKO.1-puro lentiviral vectors (26 citations) PLKO lentiviral vector (7 citations) PLKO.1 vector (90 citations) PLKO vector (19 citations) Lentiviral vector (9 citations) PLKO.1 (97 citations)

2 protocols using lentiviral vectors plko 1

Targeted Knockdown of ATF4 in TT Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lentiviral vectors (pLKO.1) containing ATF4-specific shRNAs were purchased from Sigma-Aldrich. Lentiviral ATF4-shRNA plasmids were co-transfected into HEK293T cells along with packaging (VPR8.9) and envelope (VSV-G) plasmids using X-tremeGENE (Roche) for 2 days. The virus particles containing ATF4-shRNA or control shRNA were used to infect TT cells. Transfected cells were selected in media containing 2 μg/mL puromycin (Clontech).

Bagheri-Yarmand R., Sinha K.M., Li L., Lu Y., Cote G.J., Sherman S.I, & Gagel R.F. (2018). Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Molecular cancer research : MCR, 17(3), 751-760.

+ Open protocol

+ Expand

Lentiviral Knockdown of RET and IGFBP2

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lentiviral vectors (pLKO.1) containing RET and IGFBP2-specific shRNAs or pLK0.1-puro non-target shRNA control (shRNA insert) do not target any known genes from any species) were purchased from Sigma-Aldrich. Lentiviral control shRNA or RET-shRNAs or IGFBP2-shRNA plasmids were co-transfected into 293T cells along with packaging (VPR8.9) and envelope (VSV-G) plasmids for two days. The virus particles containing RET-shRNA, IGFBP2-shRNA, or control shRNA were used to infect TT or MZCRC1 cells. Transfected cells were selected in media containing 2 μg/ml of puromycin (Takara Bio).

Bagheri-Yarmand R., Dadu R., Ye L., Jebaraj Y.S., Martinez J.A., Ma J., Tarapore R.S., Allen J.E., Sherman S.I., Williams M.D, & Gagel R.F. (2021). ONC201 shows potent anti-cancer activity against medullary thyroid cancer via transcriptional inhibition of RET, VEGFR2, and IGFBP2. Molecular cancer therapeutics, 20(4), 665-675.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!